Will Soghikian
Stock Analyst at Leerink Partners
(n/a)
# 5,069
Out of 5,074 analysts
7
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Will Soghikian
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTB Connect Biopharma Holdings | Initiated Coverage: Buy | $4 | $0.7621 | +424.87% | 1 | Oct 12, 2026 | |
| EQ Equillium | Initiated Coverage: Buy | $6 | $1.27 | +372.44% | 1 | Oct 12, 2026 | |
| EPA: GNFT Genfit S.A. | Initiated Coverage: Buy | €15.00 | €8.89 | +68.73% | 1 | Oct 12, 2026 | |
| NKTR Nektar Therapeutics | Initiated Coverage: Buy | $130 | $38.65 | +236.35% | 1 | Oct 12, 2026 | |
| PTGX Protagonist Therapeutics | Initiated Coverage: Buy | $190 | $139.53 | +36.17% | 1 | Oct 12, 2026 | |
| QTTB Q32 Bio | Initiated Coverage: Buy | $40 | $8.80 | +354.55% | 1 | Oct 12, 2026 | |
| VERA Vera Therapeutics | Initiated Coverage: Hold | $34 | $29.05 | +17.04% | 1 | Oct 12, 2026 |
Connect Biopharma Holdings
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $0.7621
Upside: +424.87%
Equillium
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $6
Current: $1.27
Upside: +372.44%
Genfit S.A.
Oct 12, 2026
Initiated Coverage: Buy
Price Target: €15.00
Current: €8.89
Upside: +68.73%
Nektar Therapeutics
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $130
Current: $38.65
Upside: +236.35%
Protagonist Therapeutics
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $190
Current: $139.53
Upside: +36.17%
Q32 Bio
Oct 12, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $8.80
Upside: +354.55%
Vera Therapeutics
Oct 12, 2026
Initiated Coverage: Hold
Price Target: $34
Current: $29.05
Upside: +17.04%